Transcranial Photobiomodulation to Augment Lithium in Bipolar-I Disorder.

What the authors concluded

All four patients had been clinically diagnosed with type-I BPAD and followed by their psychiatrist (P.M.)" "All patients reported a marked reduction of anhedonia/apathy and increase of libido, together with isolated improvements in anxiety, sleep, irritability, and impulsivity. Noticeably, the magnitude of the clinical improvement was such that little or no changes in concomitant psychotropics

Devices that emit this wavelength

Matched on wavelength within 15nm, since LED bins vary by roughly that much and a tighter match would be false precision. Where we have an irradiance figure, the session length is the time needed to reach this study's dose of 40 J/cm² at that intensity.

Matching a wavelength is not the same as reproducing a trial. Session times assume the device's published irradiance is accurate at the distance it was measured, which on brand-claim figures is often optimistic. Where a device publishes both a peak and an average we use the average, and where it publishes a falloff curve we use the lowest figure, so these times run long rather than short. Clinical protocols also control for spot size, contact and skin type in ways a home device cannot.